1398P Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES
| Autor: | Petrylak, D.P., Azad, A.A., Szmulewitz, R.Z., Iguchi, T., Shore, N.D., Holzbeierlein, J., Alekseev, B., El-Chaar, N.N., Rosbrook, B., Ma, J., Zohren, F., Haas, G.P., Stenzl, A., Armstrong, A.J. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1183-S1184 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|